Prophylaxis for Pneumocystis jiroveci pneumonia: Is it a necessity in pulmonary patients on high-dose, chronic corticosteroid therapy without AIDS?

Expert Review of Respiratory Medicine

Volumn 9, Issue 2, 2015, Pages 171-181

  Liebling, Maryjane ^a   Rubio, Edmundo ^a   Ie, Susanti ^a  

^a CARILION CLINIC   (United States)

Author keywords

asthma; chronic obstructive pulmonary disease; corticosteroids; cryptogenic organizing pneumonia; immunosuppression; interstitial lung disease; Pneumocystis jirovecii pneumonia; prophylaxis; sarcoidosis; trimethoprim sulfamethoxazole

Indexed keywords

CORTICOSTEROID; COTRIMOXAZOLE; ANTIINFECTIVE AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DISEASE PREDISPOSITION; DRUG MEGADOSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LONG TERM CARE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PNEUMOCYSTIS PNEUMONIA; REVIEW; CHEMICALLY INDUCED; DRUG ADMINISTRATION; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; MICROBIOLOGY; OPPORTUNISTIC INFECTIONS; PATHOGENICITY; PNEUMOCYSTIS JIROVECI; PNEUMONIA, PNEUMOCYSTIS; PRACTICE GUIDELINE; PROCEDURES; RISK FACTOR; STANDARDS; TIME; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOCOMPROMISED HOST; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 84924971543     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.1002471     Document Type: Review

References (96)

1. Sepkowitz KA, Brown AE, Armstrong D. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 1995;155(11):1125-8
2. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002;34(8):1098-107
3. Sepkowitz KA. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? Mayo Clin Proc 1996; 71(1):102-3
4. Hughes WT, Rivera GK, Schell MJ, et al. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316(26):1627-32
5. Rubin E, Zak F. Pneumocystis carinii pneumonia in the adult. N Engl J Med 1960;262:1315-17
6. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297(26):1419-26
7. Hardy AM, Wajszczuk CP, Suffredini AF, et al. Pneumocystis cariniipneumonia in renal transplant patients treated with cyclosporine and steroids. J Infect Dis 1984;149:143-7
8. Hofflin JM, Potasman I, Baldwin JC, et al. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987;106: 209-16
9. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: A review of ten year's experience. Rev Infect Dis 1982;4: 1119-32
10. Dummer JS, Montero CG, Griffith BP, et al. Infections in heart-lung transplants. Transplantation 1986;41:725-9
11. Gryzan S, Paradis IL, Zeevi A, et al. Unexpectedly high incidence if Pneumocystis carinii infection after lung-heart transplantation: implications for lung defense and allograft survival. Am Rev Respir Dis 1988;137:1268-74
12. LaClair RA. Transplantation pneumonia associated with Pneumocystis carinii among recipients of cardiac transplants. Am Rev Respir Dis 1969;100:874-5
13. Narins B, Jessup M. Pneumocystis carinii pneumonia after heart transplantation: A growing problem. J Heart Transplant 1990;9:67; Abstract 51
14. Olsen SO, Renlund DG, O'Connell JB, et al. Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim-sulfamethaxazole. Transplantation 1993;56:359-62
15. Stringer J, Beard C, Miller R, Wakefield A. A new name for Pneumocystis from humans and new perspectives on the host-pathogen relationship. Emerg Infect Dis 2002;8(9):891-6
16. Frenkel JK. Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): A critical historical overview. J Eukaryot Microbiol 1999;46:89S-92S
17. Sepkowitz KA, Brown AE, Telzak EE, et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267(6):832-7
18. Graham BS. Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med 1984;101(3):334-8
19. Berney S. Characterization of glucocorticosteroid-induced changes in lymphocyte circulation in the rat. Clin Res 1974;22:141A
20. Moorhead JW, Claman HN. Thymus-derived lymphocytes and hydrocortisone: identification of subsets of theta-bearing cells and redistribution to bone marrow. Cell Immunol 1972;5:74
21. Fauci AS, Dale DC. The effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood 1975;46:235
22. Brahim F. Marrow lymphocyte production during chronic hydrocortisone administration. J Reticuloendothel Soc 1978;23:111
23. Slade JD, Hepburn B. Prednisone-induced alterations of circulating human lymphocyte subsets. J Lab Clin Med 1983;101(3): 479-87
24. Walzer PD, Powell RD Jr, Yoneda K, et al. Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia. Infect Immun 1980;27(3): 928-37
25. Farr RW. Pneumocystis carinii pneumonia due to corticosteroids. South Med J 1992; 85(1):52-3
26. Huynh-Do U, Gantenbein H, Binswanger U. Pneumocystis carinii pneumonia during immunosuppressive therapy for antineutrophil cytoplasmic autoantibody-positive vasculitis. Arch Intern Med 1995;155(8):872-4
27. Frenkel JK, Good JT, Shultz JA. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab Invest 1966;15(10): 1559-77
28. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82(9):1052-9
29. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: Associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996;71(1):5-13
30. Ognibene FP, Shelhamer JH, Hoffman GS, et al. Pneumocystis cariniipneumonia: A major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995;151:795-9
31. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993;17(Suppl 2):S416-22; Review
32. Saito K, Nakayamada S, Nakano K, et al. Detection of Pneumocystis carinii by DNA amplification in patients with connective tissue dieases: re-evaluation of clinical features of P. carinii pneumonia in rheumatic diseases. Rheumatology (Oxford) 2004;43(4):479-85
33. Slivka A. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 1993; 94(2):216-19
34. Kozeny GA, Quinn JP, Bansal VK, et al. Pneumocystis carinii pneumonia: A lethal complication of "pulse" methylprednisolone therapy. Int J Artif Organs 1987;10(5): 304-6
35. Wing EJ, Bruns FJ, Fraley DS, et al. Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 1980;244:2423-6
36. Vidal S, de la Horra C, Martin J, et al. Pneumocystis jirovecii colonization in patients with interstitial lung disease. Clin Microbiol Infect 2006;12(3):231-5
37. Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 2000;164:3755-63
38. Prevost MC, Escamilla R, Aliouat EM, et al. Pneumocystosis pathophysiology. FEMS Immunol Med Microbiol 1998;22: 123-8
39. Limper AH, Offord KP, Smith TF, et al. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989;140(5): 1204-9
40. Bozzette SA. The use of corticosteroids in Pneumocystis carinii pneumonia. J Infect Dis 1990;162(6):1365-9
41. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1990;323(21):1451-7
42. Schnipper S, Small CB, Lehach J, et al. Pneumocystis carinii pneumonia presenting as asthma: increased bronchial hyperresponsiveness in Pneumocystis carinii pneumonia. Ann Allergy 1993;70(2):141-6
43. Thomas CF Jr, Limper AH. Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without aquired immune deficiency syndrome. Semin Respir Infect 1998;13(4):289-95; Review
44. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: A comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984;100(5):663-71
45. Monnet X, Vidal-Petiot E, Osman D, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 2008;12(1):R28
46. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000;118:704-11
47. Mikaelsson L, Jacobsson G, Andersson R. Pneumocystis pneumonia-a retrospective study 1991-2001 in Gothenburg, Sweden. J Infect 2006;53:260-5
48. Ewig S, Bauer T, Schneider C, et al. Clinical characteristics and outcome of Pneumocystis carinii pneumonia in HIV-infected and otherwise immunosuppressedpatients. Eur Respir J 1995;8:1548-53
49. Asai N, Motojima S, Ohkuni Y, et al. Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection. J Infect Chemother 2012;18:898-905
50. Nevez G, Raccurt C, Jounieaux V, et al. Pneumocystosis versus pulmonary Pneumocystis carinii colonization in HIV-negative and HIV-positive patients. AIDS 1999;13(4):535
51. De Boer M, Bruijnesteijn van Coppenraet L, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007;44(9):1143-9
52. Rabodonirina M, Vanhems P, Couray-Targe S, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with hiv-infected patients. Emerg Infect Dis 2004;10(10): 1766-73
53. Chave JP, David S, Wauters JP, et al. Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: A cluster of Pneumocystis carinii pneumonia in renal transplant recipients. AIDS 1991;5(8):927-32
54. Vargas SL, Ponce CA, Gigliotti F, et al. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J Clin Microbiol 2000; 38(4):1536-8
55. Gutierrez S, Respaldiza N, Campano E, et al. Pneumocystis jirovecii colonization in chronic pulmonary disease. Parasite 2011; 18(2):121-6
56. Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: A prospective study. BMC Infect Dis 2009;9:47
57. Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27(1):143-50
58. Varela JM, Respaldiza N, Sanchez B, et al. Lymphocyte response in subjects with chronic pulmonary disease colonized with Pneumocystis jirovecii. J Eukaryot Microbiol 2003;50(Suppl):672-3
59. Gutierrez S, Respaldiza N, Campano E, et al. Pneumocystis jirovecii colonization in chronic pulmonary disease. Parasite 2011;18:121-6
60. Zalacain R, Sobradillo V, Amilibia J, et al. Redisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999;13(2):343-8
61. Monso E, Rosell A, Bonet G, et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur Respir J 1999;13(2):338-42
62. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57(9): 759-64
63. Murphy T. The many faces of Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Clin Infect Dis 2008;47(12):1534-6
64. Garces Jarque JM, Terradas Robledo R, Alvarez-Lerma F, et al. Lung aspergillosis. Role of the corticoids as associated risk factor in the patient with chronic bronchitis. Rev Clin Esp 2003;203(10):472-4
65. Johnson D. Chronic candidal bronchitis: A consecutive series. Open Respir Med J 2012;6:145-9
66. Nseir S, Jozefowicz E, Cavestri B. Impact of antifungal treatment on Candida-Pseudomonas interaction: A preliminary restrospective case-control study. Intensive Care Med 2007;33(1): 137-42
67. Jiva T, Jacoby H, Weymouth L, et al. Mycobacterium xenopi: innocent Bystander or Emerging Pathogen? Clin Infect Dis 1997;24(2):225-32
68. Morris A, Sciurba FC, Norris KA. Pneumocystis: A novel pathogen in chronic obstructive pulmonary disease? COPD 2008;5(1):43-51
69. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012;25(2): 297-317
70. Morris A, Sciurba FC, Lebedeva IP, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004;170(4):408-13
71. Fleury J, Escudier E, Pocholle MJ, et al. Cell population obtained by bronchoalveolar lavage in Pneumocystis carinii pneumonitis. Acta Cytol 1985;29:721-6
72. Baughman RP, Dohn MN, Frame PT. Generalized immune response toPneumocystis carinii infection in the lung. J Protozool 1991;38:187S-8S
73. Jensen BN, Lisse IM, Gerstoft J, et al. Cellular profiles in bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms: relation to diagnosis and prognosis. AIDS 1991;5:527-33
74. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008;197(1):10-17
75. Calderon EJ, Rivero L, Respaldiza N, et al. Systemic inflammation in patients with chronic obstructive pulmonary disease who are colonized with Pneumocystis jiroveci. Clin Infect Dis 2007;45:e17-19
76. Maskell NA, Waine DJ, Lindley A, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: A prospective study. Thorax 2003;58(7):594-7
77. CDC. Recommendations for prophylaxis against P. carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Recomm Rep 1992;41(RR-4):1-11
78. Fauci AS, Macher AM, Longo DL, et al. NIH Conference: Acquire Immunodeficiency Syndrome; Epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med 1984;100:92-106
79. Hughes WT, Price RA, Kim HK, et al. Pneumocystis carinii pneumonitis in children with malignancies. J Pediatr 1973;82:404-15
80. Hughes WT, Feldman S, Aur RJA, et al. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975;36:2004-9
81. Siegel SE, Nesbit ME, Baehner R, et al. Pneumonia during therapy for childhood acute lymphoblastic leukemia. Am J Dis Child 1980;134:28-34
82. Cyklis R, Zielinska A. Pneumocystis cariniiinfection in children with acute leukemia and non-Hodgkin malignant lymphoma. Pediatr Pol 1983;58:337-40
83. De Castro N, Neuville S, Sarfati C, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: A 6-year retrospective study. Bone Marrow Transplant 2005;36:879-83
84. Schürmann M, Schürmann D, Schindler R, et al. Impaired thymic function and CD4+ T lymphopenia, but not mannose-binding lectin deficiency, are risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients. Transpl Immunol 2013;28(4):159-63
85. Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: A retrospective study 2002-2004. Scand J Infect Dis 2007; 39(6-7):589-95
86. Mansharamani NG, Balachandran D, Vernovsky I, et al. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000; 118(3):712-20
87. Nevez G, Raccurt C, Vincent P, et al. Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: Assessing risk with blood CD4+ T cell counts. Clin Infect Dis 1999;29(5):1331-2
88. Sinicco A, Maiello A, Raiteri R, et al. Pneumocystis carinii in a patient with pulmonary sarcoidosis and idiopathic CD4+ T lymphocytopenia. Thorax 1996;51:446-7
89. Gluck T, Geerdes-Fenge HF, Staub RH, et al. Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 2000;28:227-30
90. Lams BE, Sousa AR, Rees PJ, et al. Immunopathology of the small-airway submucosa in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158(5 Pt 1): 1518-23
91. Cruciani M, Marcati P, Malena M, et al. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 2002;20:982-9
92. Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011;11:76
93. Azoulay E, Bergeron A, Chevret S, et al. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009;135: 655-61
94. Mühlethaler K, Bögli-Stuber K, Wasmer S, et al. Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J 2012;39:971-8
95. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-ß-Dglucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 2012;50(1): 7-15
96. Karageorgopoulous DE, Qu JM, Korbila IP, et al. Accuracy of ß-D-glucan for the diagnosis of Pneumocystic jirovecii pneumonia: A meta-analysis. Clin Microbiol Infect 2013;19:39-49